Drugs / BAY2253651
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03603678 | Aug 2018 → May 2019 | obstructive sleep apnea syndrome | Bayer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 2253651 | “BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN).” PMID 34531274 ↗ Nov 2021 |
| Action | Inhibit | “potassium channel blocker” PMID 34531274 ↗ Nov 2021 |
| Route | Intranasal | “100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally” NCT03603678 ↗ |